Eli Lilly and Amylin Pharmaceuticals are jointly developing an exenatide once weekly pen device, which should provide a more convenient way for diabetics to treat themselves.
Amylin Pharmaceuticals is expanding significantly on the US
manufacturing facility it is building in West Chester, Ohio for a
long-acting version of its injectable diabetes drug Byetta
(exenatide).
A cartridge shortage that forced Amylin and Eli Lilly to ask 40,000
physicians in the US to stop prescribing their injectable diabetes
drug Byetta to new patients has come to an end thanks to a boost in
production by contract manufacturer...
As the shortage of cartridges of its injectable diabetes drug
Byetta reaches critical levels, Amylin Pharmaceuticals is seeking
to expand manufacturing capacity and is exploring a nasal spray
formulation of the medicine with drug...